posttraumatic stress disorder PTSD
Conditions
Interventions
Both groups will follow intensive treatment for 5 days at the clinic, with two trauma focused therapy sessions per day (Prolonged Exposure (PE) in the morning, Eye Movement Desensitisation Reprocessin
Sponsors
ARQ Centrum'45
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Diagnosis of PTSD established with the CAPS-5-R.18 years or older.Sufficient mastery of the Dutch language.Signed approval by their treating physician stating no medical conditions that would pose a risk when doing exercise at 65-85% of their maximum heart rate (e.g., cardiovascular disease).Having previously received at least one guideline-recommended trauma-focused treatment of a minimum of 8 sessions.Embedded in an onging treatment setting beyond the program.
Exclusion criteria
Exclusion criteria: Current psychotic episode, current severe alcohol or substance use disorder.Showing imminent suicidal risk (reporting suicidal plan and intent).Current use of benzodiazepines.Impossibility to isolate 5 traumatic memories that can be used for selection of the treatment plan during the program.A physical disorder or impairment that might be exacerbated by aerobic exercise (e.g., hernia).Cardiovascular conditions resulting in exercise restriction (e.g., severe heart failure, severe valvular heart disease, recent myocarditis and/or myocardial infarction, or severe cardiac arrhythmias). Active skin conditions in the contact area of the elastic chest-belt heart rate monitor (anterior thorax), including active eczema, active psoriasis, open wounds or ulcers, skin infections (bacterial, viral, fungal), burns, recent scars <3 months, severe acne, severe scarring, and other dermatoses with evident skin abnormalities Known allergy to materials used in chest-belt, including thermoplastic polyurethane, polyester, elastane, and polyamide, or a history of allergic contact dermatitis to similar materials.Current pregnancy or planning to become pregnant within the next 7 months (study duration), due to changes in BDNF and HRV levels during pregnancy (Bester et al., 2023; Brown et al., 2021; Christian et al., 2016; Sarhaddi et al., 2022; Vega et al., 2011).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcomes are changes in PTSD symptoms measured with the Clinician-administered PTSD scale for DSM-5 Revised (CAPS-5-R), depressive symptoms measured with Beck’s Depression Inventory-II (BDI-II), and BDNF measured in serum from pre- to post-treatment, three- and six-months follow-up between the experimental and control group. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secundary outcomes are the BDNF Val66Met polymorphism, heart rate variability (HRV), verbal memory measured with the Verbal Learning and Memory Test (VLGT), and executive functioning measured with the Trial Making test (TMT). | — |
Countries
Netherlands
Contacts
Public ContactM.d.C. Zepeda Méndez
ARQ Centrum'45
Outcome results
None listed